Protagonist Therapeutics Inc PTGX

NAS: PTGX | ISIN: US74366E1029 17/05/2024

30,74 USD (-3,76%)

(-3,76%) 17/05/2024

Grafiek Protagonist Therapeutics Inc

Grafiek Protagonist Therapeutics Inc

1 dag1d -3,76%
1 week1w 4,84%
1 maand1m 15,52%
3 maanden3m 12,89%
6 maanden6m 78,31%
1 jaar1j 20,08%
5 jaar5j 189,73%

Protagonist Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

12 mei 2023 · Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 · Persbericht

11 mei 2023 · Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference · Persbericht

11 mei 2023 · Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association · Persbericht

4 mei 2023 · Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

7 maart 2023 · Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis · Persbericht

21 december 2022 · Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2022 · Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit · Persbericht

16 november 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

8 november 2022 · Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

3 november 2022 · Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting · Persbericht

Profiel Protagonist Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 99

Aandelen Protagonist Therapeutics Inc

Beurswaarde: 1,80 miljard USD

Effecten: 58,65 miljoen

Beta: 1,35

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe